A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Cullinan Therapeutics, Inc.
CGEM
$799M
Mkt Cap
$17.10
-1.04%
Cullinan Therapeutics, Inc. (CGEM) has a 5-year average return on invested capital (ROIC) of -10.3%. This is below average and may indicate limited pricing power.
Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.1B. It is classified as a small-cap stock.
Cullinan Therapeutics, Inc. (CGEM) does not currently pay a regular dividend.
Cullinan Therapeutics, Inc. (CGEM) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Cullinan Therapeutics, Inc. (CGEM) generated $-128 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cullinan Therapeutics, Inc. (CGEM) reported earnings per share (EPS) of $2.38 in its most recent fiscal year.
The Ledger Terminal provides 3 years of financial data for Cullinan Therapeutics, Inc. (CGEM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
We are a clinical-stage biopharmaceutical company dedicated to creating new standards of care for patients. Our strategy is to identify high-impact targets, which we define as those that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer, and then select what we believe is the optimal therapeutic modality for those targets. We source innovation both internally and externally, focusing on product candidates with novel technology or differentiated mechanisms. Before we advance a product candidate into clinical development, we evaluate its potential for activity as a single agent as well as its ability to generate an immune response or to inhibit disease processes. Using this strategy, we have built a broad and deep pipeline of targeted immunology and oncology programs that includes multiple distinct clinical-stage product candidates.
| Metric | TTM | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 |
| Net Income | -221M | 111M | -66M | -52M |
| EPS | $-3.69 | $2.38 | $-1.52 | $-2.60 |
| Free Cash Flow | 0 | -128M | -43M | -30M |
| ROIC | -1329.0% | 19.7% | -15.5% | -35.0% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | - | - | 0.07 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -240M | 153M | -68M | -60M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -60.4% | - | - | -35.0% |
| Shares Outstanding | 61M | 47M | 43M | 20M |
| Metric | ||||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 43M | 58M | 92M | 188M |
| SG&A | 17M | 29M | 40M | 52M |
| EBIT | -60M | -68M | 153M | -240M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -52M | -66M | 111M | -221M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 77K | 77K |
| Returns on Capital | ||||
| ROIC | -35.0% | -15.5% | 19.7% | N/M |
| ROE | -35.0% | N/A | N/A | -60.4% |
| ROA | -46.0% | -20.1% | 22.3% | -54.9% |
| Cash Flow | ||||
| Op. Cash Flow | -30M | -43M | -127M | -179M |
| Free Cash Flow | -30M | -43M | -128M | 0 |
| Owner Earnings | -45M | -68M | -155M | -213M |
| CapEx | 10K | 0 | 1.1M | 0 |
| Maint. CapEx | 62K | 53K | 93K | 314K |
| Growth CapEx | 0 | N/A | 1.0M | 0 |
| D&A | 62K | 53K | 93K | 314K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 6.6M | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 15M | 24M | 28M | 34M |
| Debt Repayment | 0 | 0 | 2.2M | 2.2M |
| Balance Sheet | ||||
| Net Debt | N/A | N/A | -462M | -352M |
| Cash & Equiv. | 168M | 60M | 156M | 352M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.07 | N/A | N/A | 0.00 |
| Interest Coverage | N/A | N/A | 4792.7 | 4792.7 |
| Equity | 199M | N/A | N/A | 366M |
| Total Assets | 215M | 437M | 561M | 403M |
| Total Liabilities | 14M | N/A | N/A | 37M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -93M | -159M | -48M | -638M |
| Working Capital | 198M | 285M | 452M | 326M |
| Current Assets | 212M | 297M | 474M | 361M |
| Current Liabilities | 14M | 12M | 22M | 35M |
| Per Share Data | ||||
| EPS | -2.60 | -1.52 | 2.38 | -3.69 |
| Owner EPS | -2.25 | -1.57 | -3.31 | -3.47 |
| Book Value | 9.99 | N/A | N/A | 5.96 |
| Cash Flow/Share | -1.49 | -1.01 | -2.71 | -3.59 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 19.9M | 43.1M | 46.7M | 61.5M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | 4.3 | -4.6 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 2.9 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -6.3% | -27.0% | N/A |
| Market Cap | N/A | 685M | 473M | 1.1B |
| Avg. Price | N/A | 29.36 | 12.69 | 17.10 |
| Year-End Price | N/A | 15.87 | 10.12 | 17.10 |
Cullinan Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +13.6%.